Published in Cancer Weekly, July 20th, 2004
Dr. Qingquan Tang, group leader of virology at Intradigm, is the principle investigator of this grant titled "Development of RNAi Therapeutics for Eye Neovascularization Diseases."
This lead product has demonstrated strong antiangiogenesis effect through a dual targeting to both neovasculature in eyes and factors in VEGF pathway. VEGF pathway is the validated therapeutic target for treatment of angiogenesis related...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.